About
Corporate Overview
Founders
Management
Scientific Advisory Board
Board of Directors
Board of Advisors
Partnerships
Videos
ACP Testimonials
CEO Updates
News
Technology
Technology Overview
Manufacturing
Intellectual Property
Publications
Clinical Pipeline
ACP-01 Phase II Clinical Trial for CLI
CLI Phase II Trial Summary
Platform
Critical Limb Ischemia
Investors
Investor Overview
Analysts
A Three Minute Summary
Public Filings
AGM Materials
News & Media
News / Press Releases
Contact
MENU ≡
About
Corporate Overview
Founders
Management
Scientific Advisory Board
Board of Directors
Board of Advisors
Partnerships
Videos
ACP Testimonials
CEO Updates
News
Technology
Technology Overview
Manufacturing
Intellectual Property
Publications
Clinical Pipeline
ACP-01 Phase II Clinical Trial for CLI
CLI Phase II Trial Summary
Platform
Critical Limb Ischemia
Investors
Investor Overview
Analysts
A Three Minute Summary
Public Filings
AGM Materials
News & Media
News / Press Releases
Contact
News & Media
all
2021
2020
2019
2018
2017
2016
2015
2014
Feb 11
/ 2021
Hemostemix Announces the Protocol First Contract and Warrant Repricing Approval
Jan 28
/ 2021
HEMOSTEMIX ANNOUNCES HS 12 – 01 CLINICAL TRIAL COMPLETION OF SUBJECTS’ FOLLOW-UP VISITS AT THE END OF MARCH AND WARRANTS EXTENTED AND REPRICED
Jan 22
/ 2021
HEMOSTEMIX ANNOUNCES THE BREAD CONTRACT WITH THE DEPARTMENT OF FOREIGN AFFAIRS, TRADE & DEVELOPMENT CANADA
Jan 04
/ 2021
HEMOSTEMIX ANNOUNCES GRANT OF STOCK OPTIONS
